Daniil Stroyakovskii

Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study

Antoinette R. Tan, Seock‐Ah Im, André Mattar et al. · The Lancet Oncology · 2020 · 165 citations

Medicine, Oncology, Pharmacology +16

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial

Justin Stebbing, Y. Baranau, Valeriy Baryash et al. · The Lancet Oncology · 2017 · 123 citations · Full text

Medicine, Oncology, Breast Oncology +13

Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)

Martin Reck, Mark A. Socinski, Federico Cappuzzo et al. · Annals of Oncology · 2017 · 45 citations · Full text

Medicine, Oncology, Pharmacology +11

Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

John Crown, Daniil Stroyakovskii, Denise A. Yardley et al. · ESMO Open · 2025 · 28 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC)

Aditya Bardia, Peter Schmid, Nadia Harbeck et al. · Cancer Research · 2022 · 13 citations

Medicine, Endocrinology, Pharmacology +16